Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 466 across all filing types
Latest filing 2024-10-10 Board/Management Inform…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen
Board/Management Information Classification · 99% confidence The document is a short announcement (1868 characters) from Gentian Diagnostics regarding the death of its founder, Dr. Erling Sundrehagen. This type of announcement concerns a key individual within the company's leadership/governance structure, specifically the founder and former CSO/Consulting Founder. This fits best under 'Board/Management Information' (MANG), which covers announcements of changes in senior management or key personnel, even in the context of death. It is not a financial report, earnings release, or a standard regulatory filing like 10-K or IR. Given the subject matter, MANG is the most appropriate classification.
2024-10-10 English
Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen
Board/Management Information Classification · 99% confidence The document is a short announcement from Gentian Diagnostics regarding the death of its founder, Dr. Erling Sundrehagen. It details his career, contributions, and the date of his passing. This type of announcement concerns a key individual within the company's leadership/history. It is not a financial report (10-K, IR), an earnings release (ER), a management change (MANG), or a director's dealing (DIRS). Since it relates to a significant figure and founder, it falls closest to Board/Management Information (MANG), which covers changes in senior management, although this is a death rather than a resignation or appointment. Given the specific definitions, MANG is the most appropriate fit for news concerning a founder/senior figure's status change. It is too specific for the general 'Regulatory Filings' (RNS) fallback.
2024-10-10 English
Gentian Diagnostics ASA awarded European patent for novel NT-proBNP reference method
Regulatory Filings Classification · 100% confidence The document is a short announcement dated September 30, 2024, from Gentian Diagnostics ASA regarding being awarded a European patent for a novel reference method for NT-proBNP determination. It details the patent application number and the technical nature of the invention (LC-MS/MS). This is a specific corporate event announcement that does not fit the definitions for major financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). It is a specific regulatory/legal update concerning intellectual property. While it relates to legal matters (LTR), the core subject is the granting of a patent, which is a specific type of corporate development announcement. Given the options, it is a general regulatory announcement about a significant corporate achievement (patent grant) that doesn't fit the more specific financial or governance categories. It is best classified as a Regulatory Filing (RNS) as a general announcement of a material event that isn't covered by other specific codes like DIRS, MANG, or CAP. It is not a Report Publication Announcement (RPA) because it is announcing the patent award itself, not the publication of a financial report.
2024-09-30 English
Gentian Diagnostics: Second quarter 2024 report
Earnings Release Classification · 100% confidence The document is titled "Second quarter and first half year 2024 results" and provides detailed financial highlights (Sales, EBITDA, Gross margin) for Q2 2024 and 1H 2024, along with operational summaries, product development updates (NT-proBNP), and strategic outlook. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year, specifically focusing on interim results. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains extensive operational and strategic detail, nor is it the full Annual Report (10-K). H1 2024
2024-08-29 English
Gentian Diagnostics: Second quarter 2024 report
Investor Presentation Classification · 100% confidence The document is explicitly titled "Q2 24 Presentation" and contains detailed financial highlights for the second quarter of 2024 (2Q24), including Sales, Gross Margin, EBITDA, P&L statements, and Balance Sheet highlights comparing 2Q24 to 2Q23. It is a presentation format designed to communicate periodic financial results and business updates to investors. This structure strongly aligns with an Investor Presentation (IP), which typically includes key financial figures and strategic updates, differentiating it from a formal, comprehensive regulatory report like a 10-K or a standalone Earnings Release (ER) which is usually just the initial press release summary. Since it is a detailed presentation covering financial performance for a specific interim period (Q2), Investor Presentation (IP) is the most appropriate classification.
2024-08-29 English
Gentian Diagnostics: Second quarter 2024 report
Earnings Release Classification · 100% confidence The document explicitly states it announces the "results for the second quarter 2024" and provides key financial highlights (Sales, Revenue, EBITDA, Gross margin) for 2Q24 and 1H24. This structure—a brief announcement of period results with key figures—is characteristic of an Earnings Release (ER). It is not a full, comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). The document length is short (2617 chars), but it contains the core results, making it an ER rather than just an RPA. Q2 2024
2024-08-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.